Complementing preclinical safety assessments through genomic analyses

Steinmetz, 2009, The basics of preclinical drug development for neurodegenerative disease indications, BMC Neurol, 9, S2, 10.1186/1471-2377-9-S1-S2 Green, 2000, Status of preclinical safety assessment for immunomodulatory biopharmaceuticals, Hum Exp Toxicol, 19, 208, 10.1191/096032700678815864 Hojelse, 2000, Preclinical safety assessment: in vitro - in vivo testing, Pharmacol Toxicol, 86, 6, 10.1034/j.1600-0773.2000.d01-2.x Kay, 2010, Applications of genetically modified tools to safety assessment in drug development, Toxicol Res, 26, 1, 10.5487/TR.2010.26.1.001 Cook, 2014, Early phase clinical trials to identify optimal dosing and safety, Mol Oncol, 9, 997, 10.1016/j.molonc.2014.07.025 Prior, 2018, Reviewing the utility of two species in general toxicology related to drug development, Int J Toxicol, 37, 121, 10.1177/1091581818760564 Dancey, 2010, Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents, Clin Cancer Res, 16, 1745, 10.1158/1078-0432.CCR-09-2167 Rifai, 2006, Protein biomarker discovery and validation: the long and uncertain path to clinical utility, Nat Biotechnol, 24, 971, 10.1038/nbt1235 Ozer, 2008, The current state of serum biomarkers of hepatotoxicity, Toxicology, 245, 194, 10.1016/j.tox.2007.11.021 Durham, 2017, Target engagement measures in preclinical drug discovery: theory, methods, and case studies, Transl Mol Med, 41 Rezaee, 2017, The importance of translatability in drug discovery, Expert Opin Drug Discov, 12, 237, 10.1080/17460441.2017.1281245 Lord, 2006, Application of genomics in preclinical drug safety evaluation, Basic Clin Pharmacol Toxicol, 98, 537, 10.1111/j.1742-7843.2006.pto_444.x Denny, 2017, 109 Humphreys, 2016, Toxicology strategies for drug discovery - present and future: introduction, Chem Res Toxicol, 29, 437, 10.1021/acs.chemrestox.6b00049 Gregory, 2018 Rudmann, 1999, Utilization of genetically altered animals in the pharmaceutical industry, Toxicol Pathol, 27, 111, 10.1177/019262339902700121 Chapman, 2009, Preclinical development of monoclonal antibodies: considerations for the use of non-human primates, MAbs, 1, 505, 10.4161/mabs.1.5.9676 Lynch, 2009, Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies, mAbs, 1, 2, 10.4161/mabs.1.1.7377 Bussiere, 2008, Species selection considerations for preclinical toxicology studies for biotherapeutics, Expert Opin Drug Metabol Toxicol, 4, 871, 10.1517/17425255.4.7.871 Eastwood, 2010, Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells, Br J Pharmacol, 161, 512, 10.1111/j.1476-5381.2010.00922.x Pai, 2018, Multiple model species selection for transcriptomics analysis of non-model organisms, BMC Bioinf, 19, 137, 10.1186/s12859-018-2278-z Doyle, 2011, The construction of transgenic and gene knockout/knockin mouse models of human disease, Transgenic Res, 21, 327, 10.1007/s11248-011-9537-3 Szabo, 2017, Cell and small animal models for phenotypic drug discovery, Drug Des Dev Ther, 11, 1957, 10.2147/DDDT.S129447 Shineman, 2011, Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies, Alzheimer's Res Ther, 3, 28, 10.1186/alzrt90 Polson, 2012, The successes and limitations of preclinical studies in predicting the pharmacodynamics and safety of cell-surface-targeted biological agents in patients, Br J Pharmacol, 166, 1600, 10.1111/j.1476-5381.2012.01916.x Simpson, 2014, Monoclonal antibodies for the therapy of cancer, BMC Proc, 8, O6, 10.1186/1753-6561-8-S4-O6 Baker, 2016, Best practices in evaluating novel biomarker fit for purpose and translatability, Drug Discov Toxicol, 489, 10.1002/9781119053248.ch42 Mikaelian, 2012, Frontiers in preclinical safety biomarkers: microRNAs and messenger RNAs, Toxicol Pathol, 41, 18, 10.1177/0192623312448939 Shah, 2015, Integrated metabolomics and genomics: systems approaches to biomarkers and mechanisms of cardiovascular disease, Circ Cardiovasc Genet, 8, 410, 10.1161/CIRCGENETICS.114.000223 Fuchs, 2011, Biomarkers for drug-induced renal damage and nephrotoxicity—an overview for applied toxicology, AAPS J, 13, 615, 10.1208/s12248-011-9301-x Guengerich, 2007, Applying mechanisms of chemical toxicity to predict drug safety, Chem Res Toxicol, 20, 344, 10.1021/tx600260a Marrer, 2010, Impact of biomarker development on drug safety assessment, Toxicol Appl Pharmacol, 243, 167, 10.1016/j.taap.2009.12.015 Souza, 2017, Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer, PLoS One, 12, 10.1371/journal.pone.0184094 Mi, 2013, Circulating MicroRNAs as biomarkers for inflammatory diseases, MicroRNA, 2, 64, 10.2174/2211536611302010007 Wang, 2009, Circulating microRNAs, potential biomarkers for drug-induced liver injury, Proc Natl Acad Sci Unit States Am, 106, 4402, 10.1073/pnas.0813371106 Bai, 2013, Strategic applications of gene expression: from drug discovery/development to bedside, AAPS J, 15, 427, 10.1208/s12248-012-9447-1 Vahle, 2018, Use of toxicogenomics in drug safety evaluation: current status and an industry perspective, Regul Toxicol Pharmacol, 96, 18, 10.1016/j.yrtph.2018.04.011 Shoda, 2017, Mechanistic modelling of drug-induced liver injury: investigating the role of innate immune responses, Gene Regul Syst Biol, 11 Vogel, 2012, Insights into the regulation of protein abundance from proteomic and transcriptomic analyses, Nat Rev Genet, 13, 227, 10.1038/nrg3185 Liu, 2016, On the dependency of cellular protein levels on mRNA abundance, Cell, 165, 535, 10.1016/j.cell.2016.03.014 Igarashi, 2014, Open TG-GATEs: a large-scale toxicogenomics database, Nucleic Acids Res, 43, D921, 10.1093/nar/gku955 Davis, 2016, The comparative toxicogenomics database: update 2017, Nucleic Acids Res, 45, D972, 10.1093/nar/gkw838 Darde, 2018, TOXsIgN: a cross-species repository for toxicogenomic signatures, Bioinformatics, 34, 2116, 10.1093/bioinformatics/bty040 Xu, 2016, Comprehensive assessments of RNA-seq by the SEQC consortium: FDA-led efforts advance precision medicine, Pharmaceutics, 8, 8, 10.3390/pharmaceutics8010008 Trapnell, 2015, Defining cell types and states with single-cell genomics, Genome Res, 25, 1491, 10.1101/gr.190595.115 Lindros, 1986, Separation of functionally different liver cell types Boone, 2015, Pathway-focused PCR array profiling of enriched populations of laser capture microdissected hippocampal cells after traumatic brain injury, PLoS One, 10, 10.1371/journal.pone.0127287 Gawad, 2016, Single-cell genome sequencing: current state of the science, Nat Rev Genet, 17, 175, 10.1038/nrg.2015.16 Wu, 2017, Single-cell transcriptional analysis, Annu Rev Anal Chem, 10, 439, 10.1146/annurev-anchem-061516-045228 Papili Gao, 2017, Sincerities: inferring gene regulatory networks from time-stamped single cell transcriptional expression profiles, Bioinformatics, 34, 258, 10.1093/bioinformatics/btx575 Wooden, 2017, Using big data to discover diagnostics and therapeutics for gastrointestinal and liver diseases, Gastroenterology, 152, 53, 10.1053/j.gastro.2016.09.065 Dhanya, 2018, In silico toxicology - a tool for early safety evaluation of drug, J Bioinform Genomics Proteomics, 3, 1030 Valerio, 2012, Application of advanced in silico methods for predictive modeling and information integration, Expert Opin Drug Metabol Toxicol, 8, 395, 10.1517/17425255.2012.664636 Mahadevan, 2011, Genetic toxicology in the 21st century: reflections and future directions, Environ Mol Mutagen, 52, 339, 10.1002/em.20653 Raies, 2016, In silico toxicology: computational methods for the prediction of chemical toxicity, Wiley Interdiscipl Rev Comput Mol Sci, 6, 147, 10.1002/wcms.1240 Niu, 2016, Potentials of single-cell biology in identification and validation of disease biomarkers, J Cell Mol Med, 20, 1789, 10.1111/jcmm.12868 Leedale, 2018, A combined in vitro/in silico approach to identifying off-target receptor toxicity, iScience, 4, 84, 10.1016/j.isci.2018.05.012 Erratum, 2018, Genetic effects on gene expression across human tissues, Nature, 553, 530, 10.1038/nature25160 Thierry-mieg, 2006, AceView: a comprehensive cDNA-supported gene and transcripts annotation, Genome Biol, 7, S12.1, 10.1186/gb-2006-7-s1-s12 Schmidt, 2018, Proteomics DB Nucleic Acids Res, 46, D1271, 10.1093/nar/gkx1029 Krupp, 2012, RNA-Seq Atlas--a reference database for gene expression profiling in normal tissue by next-generation sequencing, Bioinformatics, 28, 1184, 10.1093/bioinformatics/bts084 Uhlén, 2015, Proteomics. Tissue-based map of the human proteome, Science, 347, 1260419, 10.1126/science.1260419 Uniprot consortium, 2018, UniProt: the universal protein knowledgebase, Nucleic Acids Res, 46, 2699, 10.1093/nar/gky092 NCBI genbank, 2013, GenBank, Nucleic Acids Res, 41, D36 Herrero, 2016, Ensembl comparative genomics resources, Database, 2016, 10.1093/database/baw053 Eppig, 2005, The Mouse Genome Database (MGD): from genes to mice--a community resource for mouse biology, Nucleic Acids Res, 33, D471, 10.1093/nar/gki113 Hamosh, 2005, Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders, Nucleic Acids Res, 33, D514, 10.1093/nar/gki033 Forbes, 2015, COSMIC: exploring the world's knowledge of somatic mutations in human cancer, Nucleic Acids Res, 43, D805, 10.1093/nar/gku1075 NCBI Pubmed https://www.ncbi.nlm.nih.gov/pubmed/. Ovid Database http://www.ovid.com/site/index.jsp. Krämer, 2014, Causal analysis approaches in ingenuity pathway analysis, Bioinformatics, 30, 523, 10.1093/bioinformatics/btt703 Insightmeme Citeline pharma intelligence https://pharmaintelligence.informa.com/products-and-services/data-and-analysis/citeline-joins-informas-pharma-intelligence. Trialtrove pharma intelligence https://pharmaintelligence.informa.com/products-and-services/data-and-analysis/trialtrove. Clarivate analytics: integrity https://clarivate.com/training/training-overview-ls/integrity/. Therapeutic antibody database https://tabs.craic.com/users/sign_in. Clinical trial database https://clinicaltrials.gov/. Kupershmidt, 2010, Ontology-based meta-analysis of global collections of high-throughput public data, PLoS One, 5, 10.1371/journal.pone.0013066 Brennan, 2017, Target safety assessment: strategies and resources, Methods Mol Biol, 1641, 213, 10.1007/978-1-4939-7172-5_12 Roberts, 2018, Understanding drug targets: no such thing as bad news, Drug Discov Today, 23, 1925, 10.1016/j.drudis.2018.05.028 Knight, 2018, Pathogenesis of renal injury and gene expression changes in the male CD-1 mouse associated with exposure to empagliflozin, Toxicol Pathol, 46, 671, 10.1177/0192623318784514 Bogdanffy, 2014, Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin, Int J Toxicol, 33, 436, 10.1177/1091581814551648 Taub, 2015, Sex-, species-, and tissue-specific metabolism of empagliflozin in male mouse kidney forms an unstable hemiacetal metabolite (M466/2) that degrades to 4-hydroxycrotonaldehyde, a reactive and cytotoxic species, Chem Res Toxicol, 28, 103, 10.1021/tx500380t